Only for enjoyable, what single inventory do you assume will see big development - Web page 4

anthonypals wrote: ↑Sat Aug 26, 2023 5:09 pm
.. should you needed to wager your cash on one inventory to have big returns over the following 5+ years what wouldn’t it be and why? ..

It would not be a giant wager, however Depth Therapeutics [INTS] is a biotech whose lead product is INT230-6, which is in human scientific research for the therapy of refractory stable tumors, comparable to mushy tissue sarcoma which is in section 3 trials; and neoadjuvant and metastatic triple unfavourable breast most cancers which is in Part 2 scientific trials.

This text by E. Roudasev on SeekingAlpha is an efficient abstract.
https://seekingalpha.com/article/469303 … emailshare

From the article:
“INT230-6 has a novel mechanism of motion, because it allows intratumoral supply of two well-known anti-cancer brokers utilizing a novel supply molecule.

INT230-6 induces substantial necrosis and creates a major immune response in numerous stable tumors, thereby making a ‘vaccine impact’. Drug dosing might be excessive as a result of little or no dispersion into the bloodstream is observed, and the security profile is kind of favorable. Earlier trials in people have seen tumor stabilization and shrinkage, lengthy durations with out the formation of latest tumors, and a discount in illness signs.

Cisplastin, Vinblastine with SHAO: soluble in fats and water.

Contained in the tumor cells, the molecule disperses and the payloads exert their operate. Cisplatin binds the DNA and causes cell loss of life, and vinblastine shuts down replication. INT230-6 is ready to stay current within the tumor micro-environment, which is troublesome given the extremely dense and fatty nature of tumors.

INT230-6 doesn’t enter wholesome cells however solely most cancers cells. The drug doesn’t leak into and injury wholesome tissue. Consequently, INT230-6’s security profile seems to be somewhat benign for a therapy, the essence of which it’s to kill most cancers cells within the physique.

Depth had offered an abscopal impact, particularly measurement reductions of uninjected tumors (see additionally figures 7 and eight of the annual report), which might point out a persistent impact of the drug past the place of injection, and which I assume is linked to systemic immune activation. Systemic immune activation had already been established in preclinical work by the activation of T-cell reminiscence. “

And here’s a 2019 Forbes article on Lewis Bender, the founder and CEO of Depth Therapeutics.
https://www.forbes.com/sites/danieldamb … 4eec5f45e7